Overview

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability of multiple subcutaneous doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal